Taho Pharmaceuticals Ltd. (TPEX:6467)
Taiwan · Delayed Price · Currency is TWD 220.50
-7.00 (-3.08%)
At close: Oct 15, 2026
Taho Pharmaceuticals Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 1.98 | 8.41 | - | 1.07 | 6.36 | 6.89 |
| 1.98 | 8.41 | - | 1.07 | 6.36 | 6.89 | |
Revenue Growth | -74.53% | - | - | -83.23% | -7.71% | -44.45% |
Cost of Revenue | 0.23 | 3 | - | 1.14 | 1.3 | 1.22 |
Gross Profit | 1.75 | 5.41 | - | -0.07 | 5.06 | 5.67 |
Selling, General & Admin | 52.31 | 30.54 | 23.97 | 17.36 | 15.17 | 14.88 |
Research & Development | 192.01 | 195 | 146.16 | 106.44 | 55.21 | 63.77 |
Operating Expenses | 244.32 | 225.55 | 170.13 | 121.03 | 71.76 | 80.04 |
Operating Income | -242.57 | -220.14 | -170.13 | -121.1 | -66.71 | -74.36 |
Interest Expense | -0.42 | -0.53 | -0.9 | -1.39 | -0.53 | -0.67 |
Interest & Investment Income | 4.81 | 5.82 | 3.02 | 1.3 | 0.52 | 0.27 |
Currency Exchange Gain (Loss) | -0.4 | 0.21 | 0.34 | 0.27 | 0.2 | -0.27 |
Other Non Operating Income (Expenses) | 0.24 | 0.24 | 0.24 | 0.24 | 0.22 | 63.58 |
EBT Excluding Unusual Items | -238.34 | -214.4 | -167.44 | -120.68 | -66.3 | -11.45 |
Pretax Income | -238.34 | -214.4 | -167.44 | -120.68 | -66.3 | -11.45 |
Net Income | -238.34 | -214.4 | -167.44 | -120.68 | -66.3 | -11.45 |
Net Income to Common | -238.34 | -214.4 | -167.44 | -120.68 | -66.3 | -11.45 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 52 | 51 | 45 | 39 | 36 | 35 |
Shares Outstanding (Diluted) | 52 | 51 | 45 | 39 | 36 | 35 |
Shares Change | 5.52% | 13.40% | 17.18% | 7.73% | 3.77% | -33.75% |
EPS (Basic) | -4.58 | -4.16 | -3.69 | -3.12 | -1.84 | -0.33 |
EPS (Diluted) | -4.58 | -4.16 | -3.69 | -3.12 | -1.84 | -0.33 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -205.05 | -209.14 | -165.73 | -107.1 | -63.61 | -3.37 |
Free Cash Flow Per Share | -3.94 | -4.06 | -3.65 | -2.76 | -1.77 | -0.10 |
Gross Margin | 88.49% | 64.29% | - | -6.75% | 79.52% | 82.32% |
Operating Margin | -12244.62% | -2617.59% | - | -11359.94% | -1049.20% | -1079.46% |
Profit Margin | -12031.45% | -2549.32% | - | -11321.11% | -1042.75% | -166.19% |
Free Cash Flow Margin | -10351.03% | -2486.80% | - | -10047.00% | -1000.49% | -48.95% |
EBITDA | -238.87 | -216.67 | -168.32 | -118.54 | -57.77 | -65.25 |
D&A For EBITDA | 3.7 | 3.47 | 1.81 | 2.56 | 8.94 | 9.11 |
EBIT | -242.57 | -220.14 | -170.13 | -121.1 | -66.71 | -74.36 |